Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets [Yahoo! Finance]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
The Canadian biotech, which posted a net loss of $34.8m in Q2 financial results earlier this month, said it would focus on the advancement of lunresertib and camonsertib, as well as the RP-1664 and RP-3467 programmes while preclinical research and discovery activities will be drawn back, as per a 28 August press release. Repare has 179 employees, according to GlobalData's Pharma Intelligence Centre. The majority of those let go by the company are those working in the preclinical group, as per a 1 August SEC filing. The company stated it expects to incur charges of $1.5m–$2m relating to the restructuring, consisting of one-time cash payments for termination benefits. Repare expects to execute most of its plan by Q3 this year, saving around $15m annually that will extend its cash runway into the second half of 2026. Repare's plan to focus its operations on its clinical programmes will “maximise value for patients and our shareholders”, said Repare's CEO Lloyd M Sega. The compan
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024Business Wire
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data [Seeking Alpha]Seeking Alpha
- Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic Landscape [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioBusiness Wire
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Analyst Actions
- 9/4/24 - HC Wainwright
RPTX
Sec Filings
- 8/28/24 - Form 8-K
- 8/20/24 - Form EFFECT
- 8/7/24 - Form 8-K
- RPTX's page on the SEC website